Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Virus latency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Virus latency. Displaying page 1 of 1.
    EudraCT Number: 2017-002837-48 Sponsor Protocol Number: HEAL-1-v1.5 Start Date*: 2017-12-22
    Sponsor Name:Erasmus MC
    Full Title: HIV Eradication by combining Agents to reverse Latency in vivo (HEAL-1): a randomized controlled trial.
    Medical condition: Adults with human immunodeficiency virus type-1 infection on antiretroviral treatment with adequate viral suppression and good cellular immunity.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003215-66 Sponsor Protocol Number: MARAVITRANS Start Date*: 2012-09-26
    Sponsor Name:FIBio Hospital Universitario Ramón y Cajal
    Full Title: EFFECT OF MARAVIROC ON THE TRANSCRIPTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) IN RESTING CD4+ T LYMPHOCYTES IN PATIENTS ON ANTIRETROVIRAL TREATMENT WITH SUPPRESSED VIRAL LOAD
    Medical condition: HIV-infected patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002234-53 Sponsor Protocol Number: eCLEAR-001 Start Date*: 2016-11-14
    Sponsor Name:Department of Infectious Diseases, Aarhus University Hospital
    Full Title: Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a random...
    Medical condition: HIV persistence during initiation of antiretroviral therapy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10073675 HIV infection CDC category unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-005238-23 Sponsor Protocol Number: MCA-896 Start Date*: 2016-10-18
    Sponsor Name:Rockefeller University
    Full Title: A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP)
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020180 HIV positive LLT
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003801-28 Sponsor Protocol Number: INTEGRAL Start Date*: 2007-11-07
    Sponsor Name:Fundació de Lluita contra la SIDA
    Full Title: IMPACTO DE LA INTENSIFICACIÓN CON RALTEGRAVIR EN LA LATENCIA VIRAL DE VIH-1 EN PACIENTES CON SUPRESIÓN VIRAL COMPLETA (IMPACT OF RALTEGRAVIR INTENSIFICATION ON HIV-1 VIRAL LATENCY IN PATIENTS WITH ...
    Medical condition: Pacientes con infección de VIH-1 (Patients with HIV-1 infection).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000807 Acute HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-006065-87 Sponsor Protocol Number: MARAVIBOOST Start Date*: 2008-12-26
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: EFFICACY OF TREATMENT INTENSIFICATION WITH MARAVIROC ON HIV-1 VIRAL LATENCY IN RECENTLY INFECTED HIV-1 NAÏVE PATIENTS STARTING RALTEGRAVIR PLUS TENOFOVIR/EMTRICITABINE. (EFICACIA DE LA INTENSIFICAC...
    Medical condition: Infección por VIH-1
    Disease: Version SOC Term Classification Code Term Level
    9 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001437-36 Sponsor Protocol Number: ITACO_2780_OPBG_2022 Start Date*: 2022-07-28
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV-1 reservoir profiling
    Medical condition: perinatally HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001405-90 Sponsor Protocol Number: GS-LHON/CLIN/01 Start Date*: 2013-12-26
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 10:42:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA